CAPR: Kaos Demands Board Overhaul as Deramiocel PDUFA Looms

Update August 27, 2026: CAPR closed at $9.36 on August 26 (Polygon), up 48.8% from the $6.29 close referenced below. Oppenheimer upgraded the stock on August 25 following the FDA’s confirmation that deramiocel’s PDUFA is extended to November 22 (upper-limb-only claim).

Capricor Therapeutics (CAPR) is now a governance story as much as a regulatory one. Activist investor Kaos Capital, a Miami-based firm led by Adam Arviv, sent a letter to shareholders on August 21 demanding an immediate board meeting, two new independent directors, a board-led M&A and strategic-alternatives committee, and a cash-preservation plan. The push lands the day before Capricor’s August 22 PDUFA target action date for deramiocel, its allogeneic cardiosphere-derived cell therapy for cardiomyopathy in Duchenne muscular dystrophy (DMD).

The numbers tell the story of a single-asset biotech under pressure. CAPR closed at $6.29, down about 68% from its $19.83 late-July level. Cash fell to $237.9 million at June 30 from $318.1 million at the end of 2025, with first-half operating expenses of $79.7 million. Kaos calls the company too dependent on one regulatory outcome.

That outcome looks fragile. On July 29, the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 that the HOPE-3 trial did not provide substantial evidence of effectiveness for the cardiomyopathy claim. In response, Capricor filed an amendment narrowing the claim to upper-limb dysfunction, the endpoint where the data showed a statistically significant signal. On August 24, the FDA confirmed it extended the PDUFA to November 22, 2026, classifying the amendment as major. STAT reported on August 20 that the agency is “heading for” rejection.

Kaos says it is not asking Capricor to abandon deramiocel, which it argues “may still have meaningful value for patients.” The firm instead wants the board to stop concentrating all capital and risk in a single approval decision and to hire independent legal advisers for what it calls multiple litigation matters. If the board does not convene a meeting within 15 business days, Kaos says it will seek shareholder support to elect its nominees and replace senior management.

For readers, the activist letter is a signal that a sale or strategic review could come regardless of how the FDA rules. Capricor has paused its other pipeline work pending regulatory clarity, so a rejection would leave the company with little to fall back on. A narrow upper-limb approval, if it comes, would shrink the addressable market versus the cardiomyopathy claim the committee rejected. Either path pushes the board toward the cost and value questions Kaos is raising.

What to watch next: whether Capricor’s board engages Kaos within the 15-day window, and how the company positions itself into the November 22, 2026 PDUFA now that the FDA has formally accepted the upper-limb amendment as a major extension. For the full history of the 9-3 vote, see the AdComm coverage.

Source: Kaos Capital letter to Capricor shareholders